Press release
Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, SRN-001, Wuhan Optics Valley, canbiopharm
Pulmonary Fibrosis Pipeline Insights, DelveInsight
Pulmonary Fibrosis Overview:
Pulmonary fibrosis (PF) is a chronic, progressive lung disorder marked by excessive buildup of extracellular matrix (ECM) and structural remodeling of the lungs. This process causes tissue scarring and thickening, which hinders efficient gas exchange and leads to a steady decline in respiratory function. Clinically, the disease manifests with symptoms such as persistent shortness of breath, chronic cough, and fatigue, while imaging studies typically reveal hallmark patterns of interstitial fibrosis.
The development of PF is driven by a combination of genetic predisposition, environmental exposures, and abnormal cellular responses. A central aspect of its pathology is the disruption of normal wound-healing mechanisms. Under typical conditions, lung injury triggers a repair cascade involving inflammation, epithelial regeneration, and controlled collagen deposition. In PF, however, this process becomes dysregulated, transforming into persistent fibrosis rather than proper tissue repair. This imbalance between pro-fibrotic and anti-fibrotic signaling-most notably involving the transforming growth factor-beta (TGF-β) pathway-results in continuous fibroblast activation and excessive collagen production, ultimately causing progressive scarring within the lung interstitium.
Request for a detailed insights report on Pulmonary Fibrosis pipeline insights https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Pulmonary Fibrosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Fibrosis Therapeutics Market.
Key Takeaways from the Pulmonary Fibrosis Pipeline Report
DelveInsight's Pulmonary Fibrosis pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment.
The FDA has granted Orphan Drug Designation to taladegib, an investigational Hedgehog signaling inhibitor being explored for idiopathic pulmonary fibrosis (IPF). In a Phase 2a trial, taladegib showed promising improvements in lung volume and pulmonary vessel volume using advanced imaging biomarkers. A Phase 2b trial (WHISTLE-PF) is underway and expected to complete enrollment by 2026.
In January 2025, the FDA awarded Fast Track designation to buloxibutid, an oral drug in development for IPF. This designation is intended to expedite its review process.
Key Pulmonary Fibrosis companies such as Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, SRN-001, Wuhan Optics Valley, canbiopharma Co., Ltd., Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., Agomab Therapeutics, and others are evaluating new drugs for Pulmonary Fibrosis to improve the treatment landscape.
Promising Pulmonary Fibrosis pipeline therapies in various stages of development include BMS-986278, LYT-100, AP01, ARO-MMP7, VUM02, and others.
Pulmonary Fibrosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Fibrosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Fibrosis market.
Download our free sample page report on Pulmonary Fibrosis pipeline insights https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pulmonary Fibrosis Emerging Drugs
BMS-986278 - Bristol Myers Squibb
BMS-986278 is an oral, small-molecule lysophosphatidic acid receptor 1 (LPA1) antagonist being investigated as a novel antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis. Elevated LPA levels and LPA activation play a critical role in fibrosis development. BMS-986278 acts as a potent, full antagonist of LPA1, blocking signaling through Gi, Gq, G12, and β-arrestin pathways in both engineered human LPA1-expressing cells and primary human lung fibroblasts. The therapy is currently in Phase III clinical trials for pulmonary fibrosis.
LYT-100 - PureTech Health
LYT-100 (deupirfenidone) is in development for idiopathic pulmonary fibrosis (IPF), a rare, progressive, and life-threatening lung disease. It is a deuterated derivative of pirfenidone, designed to preserve the proven pharmacological effects and clinical efficacy of pirfenidone while offering an improved pharmacokinetic (PK) profile. Clinical studies have shown that LYT-100 demonstrates enhanced tolerability, potentially enabling longer treatment duration and better disease management. The drug is currently being evaluated in Phase II clinical trials for pulmonary fibrosis.
Pulmonary Fibrosis Companies
There are over 110 companies actively developing therapies for pulmonary fibrosis. Among them, Bristol-Myers Squibb has a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 75+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Request the Sample PDF to Get Detailed Insights About the Pulmonary Fibrosis Pipeline Reports Offerings https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Pulmonary Fibrosis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pulmonary Fibrosis Therapies and Key Companies: Pulmonary Fibrosis Clinical Trials and advancements https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pulmonary Fibrosis Pipeline Therapeutic Assessment
• Pulmonary Fibrosis Assessment by Product Type
• Pulmonary Fibrosis By Stage
• Pulmonary Fibrosis Assessment by Route of Administration
• Pulmonary Fibrosis Assessment by Molecule Type
Download Pulmonary Fibrosis Sample report to know in detail about the Pulmonary Fibrosis treatment market @ Pulmonary Fibrosis Therapeutic Assessment https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Trending Reports By DelveInsight:
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Leber's Hereditary Optic Neuropathy Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, SRN-001, Wuhan Optics Valley, canbiopharm here
News-ID: 4150659 • Views: …
More Releases from DelveInsight Business Research LLP
Mobile Clinics Market Forecast Report 2032: Size, Share, and Strategic Insights …
DelveInsight's Mobile Clinics Market Insights Report 2032 provides the current and forecast market analysis, individual leading Mobile Clinics Companies market shares, challenges, Mobile Clinics Market Drivers, barriers, trends, and key market Mobile Clinics companies in the market.
To read more about the latest highlights related to the Mobile Clinics Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/Mobile-Clinics-Market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Mobile Clinics Market…
Vein Illumination Devices Market Outlook Report 2032: Current Scenario, Growth O …
DelveInsight's Vein Illumination Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Vein Illumination Devices Companies market shares, challenges, Vein Illumination Devices Market Drivers, barriers, trends, and key market Vein Illumination Devices companies in the market.
To read more about the latest highlights related to the Vein Illumination Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key…
Bioanalytical Testing Services Market Forecast Report 2032: Size, Share, and Str …
DelveInsight's Bioanalytical Testing Services Market Insights Report 2032 provides the current and forecast market analysis, individual leading Bioanalytical Testing Services Companies market shares, challenges, Bioanalytical Testing Services Market Drivers, barriers, trends, and key market Bioanalytical Testing Services companies in the market.
To read more about the latest highlights related to the Bioanalytical Testing Services Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/bioanalytical-testing-services-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key…
Thyroid Gland Disorder Treatment Market Forecast Report 2032 by DelveInsight: Si …
DelveInsight's Thyroid Gland Disorder Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Thyroid Gland Disorder Treatment Companies market shares, challenges, Thyroid Gland Disorder Treatment Market Drivers, barriers, trends, and key market Thyroid Gland Disorder Treatment companies in the market.
To read more about the latest highlights related to the Thyroid Gland Disorder Treatment Market, get a snapshot of the key highlights entailed in the Market…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
